Market Overview

Buy OncoSec Medical's 'Shocking Solution,' HC Wainwright Says

Share:

In a report published Monday, HC Wainwright analyst Mark Breidenbach initiated coverage of OncoSec Medical Inc (NASDAQ: ONCS) with a Buy rating and a price target of $25.

The target price reflects the recent 20-for-1 reverse stock split, which reduced the total outstanding shares of common stock to about 14.8 M, as well as "a comparables analysis of similarly staged biotech companies in the immuno-oncology space."

In the report HC Wainwright noted, "OncoSec's ImmunoPulse platform utilizes electroporation to efficiently transfect plasmid DNA encoding the pro-inflammatory cytokine IL-12 into patients with injectable tumors, and is currently being evaluated in patients with melanoma and squamous cell carcinoma of the head and neck (SCCHN)."

OncoSec reported its FY3Q15 earnings at a net loss of ($6.0) M, or ($0.48) per share, higher than the HC Wainwright estimate of a net loss of ($4.7) M. The shortfall was mainly due to higher-than-expected operating expenses, including R&D and G&A spend. "Going forward, we anticipate the company to maintain an approximate $6 M quarterly burn rate," Breidenbach said.

Earlier this month, OncoSec raised $12.6 M in a public offering of 2,469,091 shares of common stock. Breidenbach estimated the company's current pro forma cash at $32.1 M, which is likely to aid the company "sustain operations until mid-2017."

"The funds may be used mainly to continue clinical development of the IL-12 program, primarily for Phase 2 trials in metastatic melanoma and SCCHN. The company plans to conduct Phase 2b IST of IL-12 electroporation in combination with Keytruda in metastatic melanoma starting in 2Q15," the report stated.

Breidenbach believes that OncoSec represents "an attractive player with significant upside for the long-term investor."

 

Related Articles

View Comments and Join the Discussion!

Posted-In: HC WainwrightAnalyst Color Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
IIVICitigroupMaintains110.0
DEBMO CapitalMaintains400.0
PRITruist SecuritiesMaintains165.0
SHAKJP MorganMaintains70.0
MABarclaysMaintains380.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com